About the Company
for sangamo therapeutics, science is a means to develop new medicines with the potential to transform the lives of patients living with serious genetic diseases. our scientists are leaders in the discovery, research and development of technologies enabling gene-based therapeutic development. currently we are conducting clinical trials, including the first ever in vivo human genome editing studies. to learn more about sangamo, visit the our website at www.sangamo.com.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $SGMO News
What You Need To Know About The Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Analyst Downgrade Today
One thing we could say about the analysts on Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - they aren't optimistic, having just ...
4 Analysts Assess Sangamo Therapeutics: What You Need To Know
In the latest quarter, 4 analysts provided ratings for Sangamo Therapeutics (NASDAQ:SGMO), showcasing a mix of bullish and bearish perspectives. The following table summarizes their recent ratings, ...
Sangamo Prices Direct Offering
Belite Retreats on Start of Clinical Trial <li /> KB Flat on Opening Chino Contour Site <li /> Generational Gap on Clean ...
Sangamo Therapeutics Inc SGMO
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Sangamo Therapeutics (NASDAQ: SGMO)
Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited ...
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that it has entered into a securities purchase agreement with institutional investors, providing for the ...
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results ...
Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced preclinical data from its proprietary adeno-associated virus (AAV ...
Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform
Unlock potential with Voyager Therapeutics as HC Wainwright initiates coverage highlights its TRACER capsid platform, ...
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
RICHMOND, Calif.--(BUSINESS WIRE)-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that it has entered into a securities purchase agreement with ...
Sangamo Therapeutics, Inc. (SGMO)
One thing we could say about the analysts on Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) - they aren't optimistic... RICHMOND, Calif., March 22, 2024--SANGAMO THERAPEUTICS ANNOUNCES PRICING OF $24. ...
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that it has entered into a securities purchase agreement with institutional investors, providing for the purchase ...
Loading the latest forecasts...